![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PRSS35 |
Gene summary for PRSS35 |
![]() |
Gene information | Species | Human | Gene symbol | PRSS35 | Gene ID | 167681 |
Gene name | serine protease 35 | |
Gene Alias | C6orf158 | |
Cytomap | 6q14.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N3Z0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
167681 | PRSS35 | ATC13 | Human | Thyroid | ATC | 9.49e-85 | 2.49e+00 | 0.34 |
167681 | PRSS35 | ATC5 | Human | Thyroid | ATC | 1.35e-88 | 2.64e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRSS35 | SNV | Missense_Mutation | c.985N>A | p.Asp329Asn | p.D329N | Q8N3Z0 | protein_coding | deleterious(0) | benign(0.216) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | |
PRSS35 | SNV | Missense_Mutation | novel | c.960G>T | p.Leu320Phe | p.L320F | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
PRSS35 | SNV | Missense_Mutation | rs375371522 | c.680N>T | p.Ala227Val | p.A227V | Q8N3Z0 | protein_coding | tolerated(0.48) | benign(0.001) | TCGA-D8-A1XS-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
PRSS35 | SNV | Missense_Mutation | rs763565235 | c.145N>A | p.Ala49Thr | p.A49T | Q8N3Z0 | protein_coding | tolerated(0.66) | benign(0) | TCGA-E9-A1RD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PRSS35 | insertion | Frame_Shift_Ins | novel | c.1125_1126insTCCCCATCCTC | p.Val376SerfsTer23 | p.V376Sfs*23 | Q8N3Z0 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
PRSS35 | insertion | In_Frame_Ins | novel | c.637_638insATATTTTGA | p.Gly213delinsAspIleLeuSer | p.G213delinsDILS | Q8N3Z0 | protein_coding | TCGA-BH-A0H0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
PRSS35 | deletion | Frame_Shift_Del | novel | c.404delN | p.Asp135AlafsTer5 | p.D135Afs*5 | Q8N3Z0 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
PRSS35 | SNV | Missense_Mutation | c.1091G>A | p.Arg364His | p.R364H | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
PRSS35 | SNV | Missense_Mutation | c.757C>T | p.Arg253Trp | p.R253W | Q8N3Z0 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A6-5667-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
PRSS35 | SNV | Missense_Mutation | c.1058N>A | p.Arg353His | p.R353H | Q8N3Z0 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-A6-6142-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |